The Immunology Revenue Reality
Immunology revenue is medication-driven and authorization-sensitive. Unlike general E/M specialties, immunology profitability often hinges on accurate specialty drug billing and payer reimbursement discipline. Small discrepancies in unit reporting can result in substantial revenue loss.
- J-code unit miscalculations
- Biologic underpayment
- Prior authorization failures
- Diagnosis-to-drug mismatch
- Infusion and injection documentation gaps
- JW/JZ modifier errors
- Medical necessity denials
- High-dollar AR tied to specialty medications
Biologic & Injection Coding Precision (CCP)
- J-code accuracy and unit reporting
- Injection and infusion time compliance
- JW/JZ modifier application
- Add-on code integrity
- Diagnosis alignment for medical necessity
Target Outcome: Reduced biologic-related denials and improved first-pass acceptance.
Pre-Treatment Authorization & Coverage Controls (FIO + EAE)
- Prior authorization validation
- Coverage confirmation for specialty medications
- Benefit and frequency monitoring
- Diagnosis-to-therapy alignment
Target Outcome: Fewer biologic reimbursement disruptions.
High-Dollar AR Optimization (AAF)
- Smart triage of high-cost therapy claims
- Payer-specific appeal playbooks
- Escalation ladder for biologic disputes
- AR > 90 monitoring by drug category
Target Outcome: Faster recovery of specialty medication revenue.
Drug-Level Reimbursement Intelligence (PRL)
- Underpayment trends by J-code
- Denial clustering by biologic type
- Reimbursement variance by payer
- Appeal overturn rates on specialty drugs
Target Outcome: Clear visibility into recurring drug-related revenue leakage.
Measurable Performance Targets
- 8–18% lift in net collections
- 15–30% reduction in biologic-related denials
- 25–40% reduction in AR > 90
- 95–98% first-pass claim acceptance
- Faster appeal resolution cycles
Compliance & Infrastructure
- HIPAA-compliant workflows with BAA signed prior to PHI exchange
- Integration with major EHR platforms including Epic, Cerner, Athenahealth, NextGen, eClinicalWorks and others
- Cybersecurity oversight via Redfort Technologies
- U.S.-based nationwide operations
Are Your Biologic and Injection Claims Being Underpaid or Denied Due to Unit Errors?
Schedule a specialized Immunology Revenue Audit and identify how coding accuracy, documentation gaps, and denial patterns are affecting your claims, AR performance, and net collections.
Schedule a FREE Audit Now